ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The CML can be effectively treated by selectively targeting BCR-ABL with small molecules tyrosine kinase inhibitors (TKIs), which by inhibiting the kinase activity, drive the cells towards apoptosis.